Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05823142 · ClinicalTrials.gov registry record · NA

Health Behavior Intervention for Adults With Type 1 Diabetes

A NA study of Type 1 Diabetes, sponsored by Emory University.

Recruiting
Registry status
NA
Development phase
300
Enrollment target
1
Study location

NCT05823142: Recruiting NA study of Type 1 Diabetes, sponsored by Emory University.

NCT05823142 is a NA study of Type 1 Diabetes that is actively recruiting participants, run by Emory University. The registered enrollment target is 300 participants, below the 765-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05823142, a NA study of Type 1 Diabetes, is actively recruiting participants, sponsored by Emory University.

RECRUITING
Registry status
NA
Development phase
300 participants
Enrollment target
1
Study location

Study Summary

Type 1 diabetes (T1D) affects approximately 2 million Americans, and only 2 in 8 young adults ages 18-31 years achieve glycemic targets (glycated hemoglobin A1C \<7.0%). Achieving glycemic targets is associated with reduced risk of micro-and macrovascular complications. Sleep deprivation leads to impaired glucose tolerance and insulin sensitivity in adults without chronic conditions and with T1D. Promoting sleep in laboratory and natural environments contributes to improvements in insulin sensitivity, glucose levels, and distress symptoms in young adults without chronic conditions and more time in range in adolescents with T1D. Multiple dimensions of sleep health (alertness, timing, efficiency, and sleep duration) are associated with better achievement of glycemic targets in adults with T1D. Therefore, sleep health dimensions are appropriate therapeutic targets to improve glucoregulation and other diabetes self-management outcomes in this population. Our primary objective is to evaluate the immediate and short-term effects of a 12-week CB-sleep intervention compared to enhanced usual care (time balanced attention control) on actigraphy- and self-report derived sleep health dimensions and diabetes self-management outcomes (glycemia and distress symptoms) over 9-months (Stage II of the NIH Model for Behavior Change, ORBIT phase III). CB-sleep is guided by principles and practices from motivational interviewing and the Transtheoretical Model of Behavior Change with interactive stage-matched sessions.

Primary Outcome

The multidimensional sleep health composite score will measure sleep regularity, satisfaction, alertness, timing, efficiency, and duration of sleep. The total possible score range is 0-6 with higher scores indicating higher or better sleep health.

Conditions Studied

Interventions

  • BEHAVIORAL CB Sleep

Study Locations (1)

Georgia

  • Emory University - Atlanta

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2023-12-20
Est. Completion 2028-12
Phase NA
Emory University

1,208 total trials

What NCT05823142 shows while recruiting

NCT05823142 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 765-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (61% lower).

The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which CB Sleep is the first listed.

NCT05823142 reports a single indexed study location in Georgia.

Frequently Asked Questions

What is clinical trial NCT05823142 about?

NCT05823142 is a clinical study titled "Health Behavior Intervention for Adults With Type 1 Diabetes". Type 1 diabetes (T1D) affects approximately 2 million Americans, and only 2 in 8 young adults ages 18-31 years achieve glycemic targets (glycated hemoglobin A1C \<7.0%). Achieving glycemic targets is associated with reduced risk of micro-and macrovascular complications. Sleep deprivation leads to im...

What is the current status of trial NCT05823142?

This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2023-12-20. Estimated completion is 2028-12.

What conditions does trial NCT05823142 study?

This clinical trial studies the following conditions: Type 1 Diabetes.

What interventions are being tested in trial NCT05823142?

The interventions under investigation include: CB Sleep (BEHAVIORAL).

Who is sponsoring clinical trial NCT05823142?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05823142 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05823142's enrollment target sits among peer trials

300 21st of 198 higher than 177 of 198 other Type 1 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05823142, the US trial registry maintained by the National Library of Medicine. NCT05823142 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.